One of the most important decisions in the history of the Food and Drug Administration is quickly approaching. By early June, the agency should have a verdict on whether to approve aducanumab, a potentially first-of-its-kind treatment for Alzheimer’s disease that became a major source of hope and controversy over the last two years.
Aducanumab is meant to the slow the cognitive decline that Alzheimer’s patients experience by combating what many believe to be the root cause of disease. Such a treatment would be in high demand, given Alzheimer’s care has been limited to medications that alleviate symptoms rather than change the disease’s course.
